// App-Quantinova.ai

SAT0174 : FLARE ASSESSMENTS IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH ANIFROLUMAB IN 2 PHASE 3 TRIALS

Researchers

Presenter

  • R. Furie

Principal Investigators

  • E. F. Morand

  • A. Askanase

  • E. Vital

  • R. Kalyani

  • G. Abreu

  • L. Pineda

  • R. Tummala

Medical Centers

  • Deakin University, Melbourne, Australia

  • Columbia University College of Physicians and Surgeons, New York, New York, United States

  • University of Leeds, Leeds, United Kingdom

  • NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, United States of America

  • Early RIA, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Locations

  • United States

  • Australia

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • MDX1333

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved